BiographyDr. Jason Faris attended medical school at the Johns Hopkins School of Medicine. Following graduation, he completed internship and residency at the Massachusetts General Hospital (MGH), and fellowship training at the Dana Farber Cancer Institute. Midway through fellowship, Dr. Faris served as a Chief Resident in the Department of Medicine at MGH. Dr. Faris currently is an attending physician with the GI Cancer program at the MGH Cancer Center, and is interested in the evaluation of new therapeutics for GI cancers. Dr Faris is the principal investigator for several clinical trials open to patients with GI Cancers.
Faris, JE, Ryan DP. Biomarker-Driven Therapy in the Neoadjuvant Treatment of Colorectal Liver Metastases. Curr Colorectal Cancer Rep 2012; 8(2):143-151
Faris JE, Ryan DP. Trees, forests, and other implications of a BRAF mutant gene signature in patients with BRAF wt disease. J Clin Oncol. 2012 Apr 20; 30(12):1255-7
Faris JE, Arnott J, et al. A phase 2 study of oral MKC-1. Invest New Drugs. 2012 Aug; 30(4):1614-20.
Faris JE, Smith MR. Metabolic sequelae associated with ADT for prostate cancer. Curr Opin Endocrinol Diabetes Obes. 2010 Jun; 17(3):240-6
Faris JE, Michaelson MD. Targeted therapies: Sunitinib vs interferon-alpha in metastatic RCC. Nat Rev Clin Oncol. 2010 Jan; 7(1):7-8
Faris JE, LaCasce AS. Primary mediastinal large B-cell lymphoma. Clin Adv Hematol Oncol. 2009 Feb; 7(2):125-33
Faris JE, Moore AF, Daniels GH. Sunitinib-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid. 2007 Nov; 17(11):1147-9.